Data presented at EURETINA 2014 showcase efficacy of EYLEA in clinical practice
Bayer HealthCare reports that data have been presented at the 14th EURETINA congress in London, showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet age-related macular degeneration (wAMD) in the real-life setting. Numerous posters presented at the congress, from centres across the UK, highlight that treatment with EYLEA has resulted in improved visual and/or anatomical outcomes in treatment-naïve and pre-treated patients.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Ophthalmology aflibercept central retinal thickness Latest News visual acuity wet age-related macular degeneration Source Type: news